Cargando…
Assessment of Median and Mean Survival Time in Cancer Clinical Trials
This cohort study assesses the relative stability of median and mean survival time estimates reported in cancer clinical trials.
Autores principales: | Das, Ananya, Lin, Timothy A., Lin, Christine, Meirson, Tomer, McCaw, Zachary R., Tian, Lu, Ludmir, Ethan B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071342/ https://www.ncbi.nlm.nih.gov/pubmed/37010873 http://dx.doi.org/10.1001/jamanetworkopen.2023.6498 |
Ejemplares similares
-
Using a Clinically Interpretable End Point Composed of Multiple Outcomes to Evaluate Totality of Treatment Effect in Comparative Oncology Studies
por: Wang, Xiaofei, et al.
Publicado: (2023) -
Systemic review of the robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect
por: Horesh, Nir, et al.
Publicado: (2022) -
Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations
por: McCaw, Zachary R, et al.
Publicado: (2022) -
Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival
time as a tool for estimating progression-free life expectancy better than the
median
por: Messori, Andrea, et al.
Publicado: (2020) -
Assessing the Impact of Complementary and Alternative Medicine Trials in Oncology
por: Ludmir, Ethan B., et al.
Publicado: (2019)